Aripiprazole: a partial dopamine D2 receptor agonist antipsychotic

Bibliography

• DAVIS KL, KAHN RS, KO G et al: Dopamine in schizophrenia: an update and a reconceptualization. Am. Psychiatry (1991) 148:1474–1486.
   PubMed Web of Science ®Google Scholar
• FARRISON PJH: Dopamine and schizophrenia-proof at last? Lancet (2000) 356:958–959.
   PubMed Web of Science ®Google Scholar
• ABI-DARGHAM A, RODENHISER J, PRINTZ D et al.: Increased baseline occupancy of D2 receptors by dopamine in schizophrenia. Proc. Natl. Acad. Sci. USA (2000) 97:8104–8109.
   PubMed Web of Science ®Google Scholar
• LEWIS DA: In pursuit of the pathogenesis and pathophysiology of schizophrenia: where do we stand? Am. I Psychiatry (2002) 159:1467–1469.
   Google Scholar
• SAWA A, SNYDER SH: Schizophrenia: diverse approaches to a complex disease. Science (2002) 296:692–695.
   PubMed Web of Science ®Google Scholar
• KECK PE Jr, McELROY SL: The new antipsychotics and their therapeutic potential. Psychiati: Ann. (1997) 27:320–321.
   Web of Science ®Google Scholar
• MELTZER HY: Role of serotonin in the action of atypical antipsychotic drugs. Clin. Neurosci. (1995) 3:64–75.
   PubMedGoogle Scholar
• GOLDSTEIN J: The new generation of antipsychotics: how atypical are they? hat. Neuropsychpharmacol (2000) 3:339–349.
   PubMed Web of Science ®Google Scholar
• MCQUADE RD, BURRIS KD, JORDAN S et al.: Aripiprazole: a dopamine-serotonin system stabilizer. Collegium Internationale Neuropsychopharmacologicum Meeting, Montreal, Canada (2002) (Abstract).
   Google Scholar
• LAWLER CP, PRIOLEAU C, LEWIS MM et al.: Interactions of the novel antipsychotic apripiprazole (OPC-14597) with dopamine and serotonin receptor subtypes. Neuropsychopharmacology (1999) 20:612–627.
   PubMed Web of Science ®Google Scholar
• CARLSSON A, KEHR W, LINDQUIST Met al.: Regulation of monoamine metabolism in the central nervous system. Pharmacol Rev (1972) 24:371–384.
   Google Scholar
• AGHAJANIAN GK, BUNNEY BS: Dopamine `autoreceptors': pharmacological characterization by microiontophoretic single cell recording studies. Naunun-Schnnedebergs Arch. Pharmacol (1977) 297:1–7.
   PubMed Web of Science ®Google Scholar
• ROTH RH: Dopamine autoreceptors: pharmacology, function, and comparison with post-synaptic dopamine receptors. Commun. Psychopharmacol (1979) 3:429–445.
   PubMedGoogle Scholar
• GALLOWAY MP, WOLF ME, ROTH RH: Regulation of dopamine synthesis in the medial prefrontal cortex is mediated by release modulating autoreceptors: studies in vivo. Pharmacol Exp. Thar. (1986) 236:689–698.
   PubMed Web of Science ®Google Scholar
• CLARK D, CARLSSON A, HJORTH S et al.: Is 3-PPP a potential antipsychotic agent? Evidence from animal behavioral studies. Eur.j Pharmacol (1982) 83:131–134.
   PubMed Web of Science ®Google Scholar
• KIKUCHI T, TOTTORI K, UWAHODO Y et al: OPC-14597, a new putative antipsychotic drug with both presynaptic dopamine autoreceptor agonist activity and postsynaptic D2 receptor antagonistic activity. Pharmacol Exp. Thar (1995) 274:329–336.
   PubMed Web of Science ®Google Scholar
• MOMIYAMA T, AMANO T, TODO N et al.: Inhibition by a putative antipsychotic quinolinone derivative (OPC-14597) of dopaminergic neurons in the ventral tegmental area. Ear: Pharmacol (1996) 310:1–8.
   PubMed Web of Science ®Google Scholar
• AMANO T, MATSUBAYASHI H, MOMIYAMA T et al: Antagonizing effects of a novel antipsychotic quinolinone derivative (OPC-14597) on dopaminergic inhibition of neuronal activities in the nucleus accumbens. Frog. Nemo-Psychopharmacol Biol. Psychiatr. (1995) 19:105–116.
   PubMed Web of Science ®Google Scholar
• MATSUBAYASHI H, AMANO T, SASA M: Inhibition by aripiprazole of dopaminergic inputs to striatal neurons from substantia nigra. Psychopharmacology (1999) 146:139–143.
   PubMed Web of Science ®Google Scholar
• INOUE T, DOMAE M, YAMADA K et al: Effects of the novel antipsychotic (OPC-14597) on prolactin release from the rat anterior pituitary gland. I Pharmacol Exp. Thar: (1996) 277:137–143.
   Google Scholar
• YAMADA S, HARANO M, YOKOO H et al: Antagonistic effects of OPC-14597, a novel antipsychotic drug, on quinpirole- and 0-sulpiride-induced changes in evoked dopamine release in rat striatal slices. Pharm. Pharmacol (1996) 49:206–208.
   Web of Science ®Google Scholar
• INOUE A, MIKI S, SETO M et al: Aripiprazole, a novel antipsychotic drug, inhibits quinpirol-evoked GTPase activity but does not up-regulate dopamine D2 receptor following repeated treatment in the rat striatum. Ear' PharmacoL (1997) 321:105–111.
   PubMed Web of Science ®Google Scholar
• BURRIS KD, MOLSKI TF, XU C et al: Aripiprazole, a novel antipsychotic, is a high- affinity partial agonist at human dopamine D2 receptors. J. Pharmacol. Exp. Thar. (2002) 302:381–389.
   PubMed Web of Science ®Google Scholar
• STAHL SM: Dopamine system stabilizers, apripiprazole, and the next generation of antipsychotic, Part 1. `Goldilocks' actions at dopamine receptors. I Clin. Psychiatry (2001) 62:841–842.
   PubMed Web of Science ®Google Scholar
• STAHL SM: Dopamine system stabilizers, aripiprazole, and the next generation of antipsychotics, Part 2. Illustrating their mechanism of action. j. Clin. Psychiatry (2001) 62:923–924.
   Google Scholar
• YOKOI F, GRUNDER G, BIZIERE K et al.: Dopamine D2 and D3 receptor occupancy in normal humans treated with the antipsychotic drug aripiprazole (OPC 14597): a study using positron emission tomography and [11C] raclopride. Neuropsychopharmacology (2002) 27:248–259.
   PubMed Web of Science ®Google Scholar
• JORDAN S, KOPRIVICA V, CHEN R et al.: The anitpsychotic aripiprazole is a potent, partial agonist at the human 5-HTIA receptor. Ear. Pharmacol. (2002) 441:137–140.
   PubMed Web of Science ®Google Scholar
• SPROUSE JS, REYNOLDS LS, BRASELTON JP et al.: Comparison of the novel antipsychotic ziprasidone with clozapine and olanzapine: inhibition of dorsal raphe cell firing and the role of 5-HT1A receptor activation. Neuropsychopharmacology (1999) 21:622–631.
   PubMed Web of Science ®Google Scholar
• BRILEY M, MORET C: Neurobiologicalmechanisms involved in antidepressant therapies. Clin. Neuropharmacol (1999) 21:387–400.
   Google Scholar
• WEINBERGER DR, LIPSKA BK: Corticalmaldevelopment, antipsychotic drugs and schizophrenia. Schizophr. Res. (1995) 16:87–110.
   PubMed Web of Science ®Google Scholar
• SHARMA RP, SHAPIRO LE: The 5-HT1A receptor system: possible implications for schizophrenic negative symptoms. Psychiatric Ann. (1996) 26:88–92.
   Web of Science ®Google Scholar
• SEMBA J, WATANABE A, KITO S et al.: Behavioral and neurochemical effects of OPC-14597, a novel antipsychotic drug, on dopaminergic mechanisms in rat brain. Neuropharmacology (1995) 34:785–791.
   PubMed Web of Science ®Google Scholar
• OZDEMIR V, FOURIE J, OZDENER F: Aripiprazole. Carr: Opin. Investig. Drugs (2002) 3:113–120.
   PubMedGoogle Scholar
• MALLIKAARJUN S, SALAZAR DE, BRAMER SL: The pharmacokinetics, tolerability and safety of aripiprazole following single and multiple oral dose administration. 22nd Collegium Internationale Neuropsychopharmacologicum Congress, Brussels, Belgium (2000) (Abstract).
   Google Scholar
• SAHA AR, ALI M, INGENITO GG et al: Safety and tolerability of aripiprazole at doses higher than 30 mg. 24th Collegium Internationale Neuropsychopharmologicum Congress, Montreal, Canada (2002) (Abstract).
   Google Scholar
• CITROME L, JOSIASSEN R, BARK N et al.: Pharmacokinetics and safety of aripiprazole & concomitant mood stabilizers. 24th Collegium Internationale Neuropsychopharmacologicum Congress, Montreal, Canada (2002) (Abstract).
   Google Scholar
• PETRIE JL, SAHA AR, MCEVOY JP: Aripiprazole, a new atypical antipsychotic: Phase II clinical trial results. Ear. Neuropsychopharmacol (1997) 7(Suppl.):S227 (Abstract).
   Google Scholar
• KANE JM, INGENITO G, ALI M: Efficacy of aripiprazole in psychotic disorders: comparison with haloperidol and placebo. Schizophr. Res. (2000) 41:39 (Abstract).
   Google Scholar
• SAHA AR, CARSON WH, ALT MW et al.: Efficacy and safety of aripiprazole and risperidone versus placebo in patients with schizophrenia and schizoaffective disorder. W J. Biol. Psychiatr. (2001) 2\(Suppl. 1):3055 (Abstract).
   Google Scholar
• MCELROY SL, KECK PE Jr: Pharmacologic agents for the treatment of acute bipolar mania. Biol. Psychiatr. (2000) 48:539–557.
   PubMed Web of Science ®Google Scholar
• TOHEN M, SANGER TM, McELROY SLet al.: Olanzapine versus placebo in the treatment of acute mania. Jim. .1 Psychiatry (1999) 156:702–709.
   Google Scholar
• TOHEN M, JACOBS TG, GRUNDY SL et al.: Efficacy of olanzapine in acute bipolar mania: a double-blind, placebo-controlled study. Arch. Gen. Psychiatry (2000) 57:841–849.
   PubMed Web of Science ®Google Scholar
• KECK PE Jr, ICE KN: Controlled treatment of acute mania with ziprasidone. Annual Meeting of the American Psychiatric Association, Chicago, IL, USA (2000) (New Research Abstract 224).
   Google Scholar
• KECK PE Jr, SAHA AR, IWAMOTO T et al.: Aripiprazole versus placebo in acute mania. Annual Meeting of the American Psychiatric Association, Philadelphia, PA, USA (2002) (New Research Abstract 314).
   Google Scholar
• Data on file. Bristol-Myers Squibb/Otsuka. Wallingford, CT, USA.
   Google Scholar
• ANDREASEN NC, FLAUM M: Schizophrenia: the characteristic symptoms. Schizophr. Bull. (1991) 17:27–49.
   PubMed Web of Science ®Google Scholar
• CORNBLATT B, KERN RS, CARSON WH et al.: An open-label comparison of the neurocognitive effects of aripiprazole compared with olanzapine in patients with stable schizophrenia. Mt. Sinai Conference on Cognition and Schizophrenia, Whistler, British Columbia, Canada (2001).
   Google Scholar
• CARSON W, PIGOTT T, SAHA A et al.: Aripiprazole versus placebo in the treatment of stable, chronic schizophrenia. 26th Collegium Internationale Neuropsychopharmacologicum Congress, Montreal, Canada (2002) (Abstract).
   Google Scholar
• KUJAWA M, SAHA A, INGENITO GG et al.: Aripiprazole for long-term maintenance treatment of schizophrenia. 26th Collegium Internationale Neuropsychopharmacologicum Congress, Montreal, Canada (2002) (Abstract).
   Google Scholar
• STOCK E, MARDER SR, SAHA A et al.: Safety and tolerability meta-analysis of aripiprazole in schizophrenia. 26th Collegium Internationale Neuropsychopharmacologicum Congress, Montreal, Canada (2002) (Abstract).
   Google Scholar
• CARSON W, SAHA A, IWAMOTO T et al.: Meta-analysis of prolactin effects with aripiprazole. 26th Collegium Internationale Neuropsychopharmacologicum Congress, Montreal, Canada (2002) (Abstract).
   Google Scholar
• JODY D, SAHA A, IWAMOTO T et al: Meta-analysis of weight effects with aripiprazole. 26th Collegium Internationale Neuropsychopharmacologicum Congress, Montreal, Canada (2002) (Abstract).
   Google Scholar
• STOCK E, SAHA A, BRUNELL R et al.: Meta-analysis of cardiac safety with aripiprazole. 26th Collegium Internationale Neuropsychopharmacologicum Congress, Montreal, Canada (2002) (Abstract).
   Google Scholar
• KECK PE Jr, McELROY SL, ARNOLD LM: Ziprasidone: a new atypical antipsychotic. Expert Opin. Pharmacother. (2001) 2:1033–1042.
   PubMedGoogle Scholar